{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:23:50Z","timestamp":1774743830921,"version":"3.50.1"},"reference-count":98,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alkermes, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S1092852922000116_sec1\"><jats:title>Background<\/jats:title><jats:p>The endogenous opioid system affects metabolism, including weight regulation. Evidence from preclinical and clinical studies provides a rationale for targeting this system to mitigate weight-related side effects of antipsychotics. This review describes the role of the opioid system in regulating weight and metabolism, examines the effects of opioid receptor antagonism on those functions, and explores the use of opioid antagonists to mitigate antipsychotic-associated weight gain and\/or metabolic effects.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852922000116_sec2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>A PubMed literature search was conducted to identify representative opioid antagonists and associated preclinical and clinical studies examining their potential for the regulation of weight and metabolism.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852922000116_sec3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>The mu opioid receptor (MOR), delta opioid receptor (DOR), and kappa opioid receptor (KOR) types have overlapping but distinct patterns of central and peripheral expression, and each contributes to the regulation of body weight and metabolism. Three representative opioid antagonists (eg, naltrexone, samidorphan, and LY255582) were identified for illustration. These opioid antagonists differed in their receptor binding and pharmacokinetic profiles, including oral bioavailability, systemic clearance, and half-life, and were associated with varying effects on food intake, energy utilization, and metabolic dysregulation.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852922000116_sec4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>Preclinical and clinical data suggest that antagonism of the endogenous opioid system is a mechanism to address antipsychotic-associated weight gain and metabolic dysregulation. However, evidence suggests that the differing roles of MOR, DOR, and KOR in metabolism, together with the differences in receptor binding, pharmacokinetic, and functional activity profiles of the opioid receptor antagonists discussed in this review, likely contribute to their differential pharmacodynamic effects and clinical outcomes observed regarding antipsychotic-associated weight gain.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852922000116","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T05:30:23Z","timestamp":1646285423000},"page":"288-299","source":"Crossref","is-referenced-by-count":12,"title":["Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine"],"prefix":"10.1017","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-9266","authenticated-orcid":false,"given":"Leslie","family":"Citrome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4764-7816","authenticated-orcid":false,"given":"Mark S.","family":"Todtenkopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marni","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0866-5245","authenticated-orcid":false,"given":"Sarah","family":"Akerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"S1092852922000116_r25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182662098"},{"key":"S1092852922000116_r29","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00626"},{"key":"S1092852922000116_r9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"S1092852922000116_r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2009.03.029"},{"key":"S1092852922000116_r79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.02.078"},{"key":"S1092852922000116_r94","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S313840"},{"key":"S1092852922000116_r89","unstructured":"89. Todtenkopf, MS . The novel opioid receptor modulator RDC-0313 (ALKS 33) reduces olanzapine-induced weight gain in female rats [oral presentation]. Presented at the Annual Meeting of the Society for Neuroscience, San Diego, CA, November 13\u201317, 2010."},{"key":"S1092852922000116_r71","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(84)90016-9"},{"key":"S1092852922000116_r53","doi-asserted-by":"publisher","DOI":"10.1210\/endo-124-3-1254"},{"key":"S1092852922000116_r8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"S1092852922000116_r48","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)90632-6"},{"key":"S1092852922000116_r2","volume-title":"Practice Guideline for the Treatment of Patients with Bipolar Disorder","author":"Hirschfeld","year":"2002"},{"key":"S1092852922000116_r83","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/cmdc.201402142","article-title":"The discovery and development of the N-substituted trans-3,4-dimethyl-4-(3\u2019-hydroxyphenyl)piperidine class of pure opioid receptor antagonists","volume":"9","author":"Carroll","year":"2014","journal-title":"ChemMedChem."},{"key":"S1092852922000116_r93","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.18030280"},{"key":"S1092852922000116_r52","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2016.03.004"},{"key":"S1092852922000116_r98","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.7075su1c.02"},{"key":"S1092852922000116_r90","doi-asserted-by":"publisher","DOI":"10.1006\/appe.1999.0284"},{"key":"S1092852922000116_r84","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.10.134"},{"key":"S1092852922000116_r95","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/85.5.1197"},{"key":"S1092852922000116_r14","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119885918"},{"key":"S1092852922000116_r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2015.08.001"},{"key":"S1092852922000116_r87","unstructured":"87. Contrave [package insert]. Morristown, NJ: Currax Pharmaceuticals LLC; 2020."},{"key":"S1092852922000116_r61","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.249839"},{"key":"S1092852922000116_r72","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00379"},{"key":"S1092852922000116_r3","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2017.1384850"},{"key":"S1092852922000116_r85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.04.050"},{"key":"S1092852922000116_r78","first-page":"916","article-title":"Disposition of the opioid antagonist, LY255582, in rats and dogs","volume":"23","author":"Swanson","year":"1995","journal-title":"Drug Metab Dispos."},{"key":"S1092852922000116_r28","doi-asserted-by":"publisher","DOI":"10.1210\/me.2008-0345"},{"key":"S1092852922000116_r77","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-019-00280-5"},{"key":"S1092852922000116_r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2012.01.019"},{"key":"S1092852922000116_r69","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(80)90008-X"},{"key":"S1092852922000116_r55","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/42.6.1175"},{"key":"S1092852922000116_r67","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(02)02955-2"},{"key":"S1092852922000116_r50","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.16090171"},{"key":"S1092852922000116_r6","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12785"},{"key":"S1092852922000116_r96","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)91698-Z"},{"key":"S1092852922000116_r68","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.3.847"},{"key":"S1092852922000116_r23","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.19121279"},{"key":"S1092852922000116_r51","doi-asserted-by":"publisher","DOI":"10.1186\/1755-7682-3-24"},{"key":"S1092852922000116_r42","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2012.179"},{"key":"S1092852922000116_r66","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/den273"},{"key":"S1092852922000116_r82","first-page":"250","article-title":"In vivo characterization of the opioid receptor binding profiles of samidorphan and naltrexone in rats: comparisons at clinically relevant concentrations [abstract T151]","volume":"45","author":"Tan","year":"2020","journal-title":"Neuropsychopharmacology."},{"key":"S1092852922000116_r13","doi-asserted-by":"publisher","DOI":"10.2165\/11589060-000000000-00000"},{"key":"S1092852922000116_r58","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112450783"},{"key":"S1092852922000116_r86","unstructured":"86. Vivitrol [package insert]. Waltham, MA: Alkermes, Inc.; 2021."},{"key":"S1092852922000116_r64","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0414-6"},{"key":"S1092852922000116_r62","unstructured":"62. Revia [package insert]. Pomona, NY: Duramed Pharmaceuticals, Inc.; 2013."},{"key":"S1092852922000116_r57","doi-asserted-by":"publisher","DOI":"10.4149\/endo_2015_04_198"},{"key":"S1092852922000116_r31","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr4066"},{"key":"S1092852922000116_r4","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12025"},{"key":"S1092852922000116_r97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.7090su1cj","article-title":"The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness","volume":"70","author":"Velligan","year":"2009","journal-title":"J Clin Psychiatry."},{"key":"S1092852922000116_r19","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-143610"},{"key":"S1092852922000116_r45","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(88)90062-5"},{"key":"S1092852922000116_r92","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.10.014"},{"key":"S1092852922000116_r17","doi-asserted-by":"publisher","DOI":"10.2165\/11596300-000000000-00000"},{"key":"S1092852922000116_r75","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12769"},{"key":"S1092852922000116_r81","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903048959"},{"key":"S1092852922000116_r59","first-page":"387","article-title":"The effect of the opioid antagonist LY255582 on body weight of the obese Zucker rat","volume":"15","author":"Shaw","year":"1991","journal-title":"Int J Obes."},{"key":"S1092852922000116_r88","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1350"},{"key":"S1092852922000116_r10","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S209284"},{"key":"S1092852922000116_r70","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(93)90557-A"},{"key":"S1092852922000116_r12","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.156"},{"key":"S1092852922000116_r15","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.7.1050"},{"key":"S1092852922000116_r22","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.12.3510"},{"key":"S1092852922000116_r30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03848-y"},{"key":"S1092852922000116_r80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.02.032"},{"key":"S1092852922000116_r38","first-page":"185","article-title":"Effects of acute or chronic opioid agonists and their modulation by diurnal rhythmicity and satiety states on food intake in rats","volume":"30","author":"Gulati","year":"1992","journal-title":"Indian J Exp Biol."},{"key":"S1092852922000116_r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2013.09.003"},{"key":"S1092852922000116_r91","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113509904"},{"key":"S1092852922000116_r27","doi-asserted-by":"publisher","DOI":"10.3758\/s13415-019-00710-6"},{"key":"S1092852922000116_r20","doi-asserted-by":"publisher","DOI":"10.1096\/fj.12-208041"},{"key":"S1092852922000116_r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2019.04.008"},{"key":"S1092852922000116_r44","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199406000-00016"},{"key":"S1092852922000116_r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2012.03.028"},{"key":"S1092852922000116_r37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1616664113"},{"key":"S1092852922000116_r36","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00406.2010"},{"key":"S1092852922000116_r49","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00632.2002"},{"key":"S1092852922000116_r54","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(86)90243-2"},{"key":"S1092852922000116_r7","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X"},{"key":"S1092852922000116_r47","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4889(86)90024-8"},{"key":"S1092852922000116_r60","doi-asserted-by":"publisher","DOI":"10.1021\/jm058261c"},{"key":"S1092852922000116_r63","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agt030"},{"key":"S1092852922000116_r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.08.005"},{"key":"S1092852922000116_r41","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2014.02.012"},{"key":"S1092852922000116_r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2007.03.012"},{"key":"S1092852922000116_r46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2005.07.013"},{"key":"S1092852922000116_r56","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119856850"},{"key":"S1092852922000116_r74","unstructured":"74. Lybalvi [package insert]. Waltham, MA: Alkermes, Inc.; 2021."},{"key":"S1092852922000116_r11","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1701823"},{"key":"S1092852922000116_r1","volume-title":"The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia","year":"2019"},{"key":"S1092852922000116_r65","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X15666170718144058"},{"key":"S1092852922000116_r16","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.11.1021"},{"key":"S1092852922000116_r76","first-page":"15","article-title":"Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration","volume":"45","author":"Meyer","year":"1984","journal-title":"J Clin Psychiatry."},{"key":"S1092852922000116_r5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31544-0"},{"key":"S1092852922000116_r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.01.013"},{"key":"S1092852922000116_r32","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/132.9.2775"},{"key":"S1092852922000116_r73","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000192"},{"key":"S1092852922000116_r26","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00005.2009"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852922000116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T09:45:41Z","timestamp":1700300741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852922000116\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1092852922000116"],"URL":"https:\/\/doi.org\/10.1017\/s1092852922000116","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]}}}